All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Updated Cosibelimab Label Reflects Long-Term Data in Advanced CSCC

December 2nd 2025

The prescribing information for cosibelimab in advanced cutaneous squamous cell carcinoma was updated to include long-term data from the CK-301-101 trial.

Hackensack Meridian Health Partners with DELFI Diagnostics, Supported by a Grant from Lilly to Improve Lung Cancer Screening Adherence With Innovative Blood Test

December 2nd 2025

The initiative aims to increase uptake of life-saving LDCT scans for high-risk individuals in line with guidance via a minimally invasive blood test.

IGV-001 Prolongs OS vs Placebo in Newly Diagnosed Glioblastoma

December 2nd 2025

IGV-001 produced an OS benefit vs placebo in newly diagnosed glioblastoma.

sNDA for Aminolevulinic Acid Gel Plus PDT in sBCC Is Submitted to the FDA

December 2nd 2025

Biofrontera has submitted a sNDA to the FDA seeking the approval of aminolevulinic acid gel plus PDT in sBCC.

Revisit Every OncLive On Air Episode From November 2025

December 2nd 2025

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

Copanlisib/Ibrutinib Data Highlight Potential for PI3K Inhibition in R/R PCNSL

December 2nd 2025

BTK and PI3K inhibition produced responses but unexpected PK data in relapsed/refractory PCNSL.

OncLive’s November Roundup of Key FDA Approvals in Oncology: 10 Decisions to Know

December 2nd 2025

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Subcutaneous Pembrolizumab Approved in EU for All Adult Indications

December 1st 2025

Pembrolizumab obtained approval from the European Commission for subcutaneous administration for all adult indications.

NICE Recommends Obe-Cel for Adult R/R B-ALL

December 1st 2025

NICE has recommended obecabtegene autoleucel for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Dana-Farber–Led Studies in Sickle Cell Disease, Waldenström’s, Follicular and Mantle Cell Lymphomas, and MDS Presented at ASH 2025

December 1st 2025

Dana-Farber Cancer Institute will present numerous presentations at ASH 2025 about studies in hematologic diseases and cancers.

CLN-049 Nets FDA Fast Track Designation in Relapsed/Refractory AML

December 1st 2025

The FDA granted fast track designation to CLN-049 for relapsed/refractory acute myeloid leukemia.

FDA Approves IsoPSA Blood-Based Prostate Cancer Test as Diagnostic Aid for High-Risk Disease

December 1st 2025

IsoPSA has been FDA approved for use as an aid in the diagnosis of high-grade prostate cancer in men at least 50 years of age with elevated PSA levels.

ctDNA and MRD Advance Toward Clinical Integration in Lymphoma

December 1st 2025

Sarah Rutherford, MD, discusses emerging roles for ctDNA and MRD in lymphoma, highlighting surveillance value, personalized assays, and evolving adoption.

Experts Unpack the Most Notable NCCN Guideline Changes Heading Into 2026

December 1st 2025

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

FDA Approval of Daratumumab Opens Treatment Options for High-Risk Smoldering Myeloma

December 1st 2025

Peter Voorhees, MD, discusses the FDA approval of daratumumab for patients with high-risk smoldering multiple myeloma.

Emerging Immunotherapy and Precision Medicine Strategies Take Aim at PDAC Treatment Resistance

November 30th 2025

Jose Trevino, MD, discusses how immunotherapy and precision medicine approaches may advance treatment for patients with immune-resistant PDAC.

Five Under 5: Top Oncology Videos for the Week of 11/23

November 30th 2025

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

The OncFive: Top Oncology Articles for the Week of 11/23

November 29th 2025

The FDA approved a new option in resectable gastric cancer, and a new agent is under priority review in mantle cell lymphoma.

Real-World Data Shows Vorasidenib Could Address Earlier Treatment Needs in IDH-Mutant Glioma

November 29th 2025

Study findings indicate potential unmet needs for early vorasidenib treatment with minimal toxicity for patients with slow-growing IDH-mutant gliomas.

Advancing Early Detection and Therapeutic Innovation Remain Critical in Pancreatic Ductal Adenocarcinoma

November 28th 2025

Jose Trevino, MD, discusses unmet needs in PDAC, highlighting early detection and multidisciplinary care amid Pancreatic Cancer Awareness Month.